FDA’s future; in vivo CAR T plays; psychedelics; CDK2 — BioCentury’s latest podcast

Who the winners and losers are likely to be as FDA changes shape

The Trump administration’s overhaul of FDA is still underway, but the agency has already veered away from its decades-long trajectory in ways that will profoundly reshape medical product development and the lives of U.S. patients. On the latest BioCentury This Week podcast, BioCentury’s analysts assess who the winners and losers are likely to be as FDA changes shape.

The analysts discuss a pair of in vivo CAR T companies:  Esobiotec S.A., whose story offers a case study in product-focused strategy, and  Capstan Therapeutics Inc., whose in vivo CAR T platform for immunological disorders attracted a buyer in  Abbvie Inc. (NYSE:ABBV). The team also analyzes why data from Compass Pathways plc (NASDAQ:CMPS) for psilocybin therapy COMP360 disappointed investors despite hitting the endpoint, and how molecular glues could be the future of selective CDK2 targeting.